This winter’s flu vaccination programme is under way, and health services are urging everyone who is eligible to take up the offer before infections peak. In England, vaccination began on 1 September 2026 for children, pregnant women and some adults, and on 1 October for most other groups, including everyone aged 65 and over, people in clinical risk groups, care home residents, carers and close contacts of immunocompromised people. The ambition is for the vast majority of vaccinations to be completed by 30 November, although the programme runs until 31 March 2027. The World Health Organization target is 75 percent uptake among adults aged 65 and over, and NHS England has set the same goal. In the United States, the CDC’s guidance for the 2026-27 season says most people who need one dose should ideally be vaccinated in September or October, and that vaccination should continue throughout the season.
What the Evidence Shows
Flu is often dismissed as a bad cold, but it can cause serious illness, hospital admission and death, particularly in older people and those with long-term conditions. The vaccine takes up to two weeks to start working, which is why health services press for early uptake rather than waiting until flu is already circulating widely. Children are a particular focus, because vaccinating them early in the season has the greatest impact on reducing transmission to others. This year the programme has also been widened, with community pharmacies able to vaccinate two- and three-year-olds and people experiencing homelessness offered a jab from 1 October. Anyone unsure whether they qualify can check with their GP or pharmacy, and booking is free for everyone in an eligible group. Health services also stress that the jab cannot give you flu, a common myth, and that mild soreness in the arm for a day or two is the most frequent side effect. Reporting and analysis from sources such as National Institutes of Health track the same developments, and specialists following flu vaccination programme say the direction is now consistent across independent lines of evidence.
The Wider Context
The wider context is a health system trying to move from treating illness late to preventing it early, against budgets that reward the opposite. Evidence around flu vaccination programme is being weighed by guideline committees that ask two questions in order: does it work, and can ordinary services actually deliver it at scale. Many good ideas pass the first test and stall on the second.
What Happens Next
What happens next for flu vaccination programme depends on the slow machinery of guidelines, funding and training catching up with the evidence. Patients asking about it today should expect honest answers that include uncertainty, and clinicians say a service that explains what is not yet known earns more trust than one that oversells. The research pipeline, at least, is moving in the right direction. You can follow related developments in our coverage of health.
None of this will be settled by a single announcement, study or product launch. The pattern to watch is accumulation: independent confirmations, honest reporting of failures and steady improvement in the underlying numbers. Readers who follow those signals, rather than the loudest claim of the week, will understand this subject better than most of the commentary surrounding it suggests is possible.

